Next Article in Journal
First Experiences with Newborn Screening for Congenital Hypothyroidism in Ulaanbaatar, Mongolia
Next Article in Special Issue
Advances in the Diagnosis and Treatment of Krabbe Disease
Previous Article in Journal
Re-Evaluation of the Prevalence of Permanent Congenital Hypothyroidism in Niigata, Japan: A Retrospective Study
Previous Article in Special Issue
Newborn Screening for Krabbe Disease—Illinois Experience: Role of Psychosine in Diagnosis of the Disease
Case Report

Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report

Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Biochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
Inherited Metabolic Specialty Center, Department of Pediatrics, Upstate Medical University, Syracuse, NY 13010, USA
NY State Newborn Screening Program, Wadsworth Center, New York State Department of Health, Al-bany, NY 13010, USA
Author to whom correspondence should be addressed.
Academic Editor: David S. Millington
Int. J. Neonatal Screen. 2021, 7(2), 28;
Received: 23 April 2021 / Revised: 19 May 2021 / Accepted: 24 May 2021 / Published: 28 May 2021
(This article belongs to the Special Issue Newborn Screening and Follow-Up Diagnostic Testing for Krabbe Disease)
Krabbe disease (KD) is a rare inherited neurodegenerative disorder caused by a deficiency in galactocerebrosidase enzyme activity, which can present in early infancy, requiring an urgent referral for hematopoietic stem cell transplantation, or later in life. Newborn screening (NBS) for KD requires identification and risk-stratification of patients based on laboratory values to predict disease onset in early infancy or later in life. The biomarker psychosine plays a key role in NBS algorithms to ascertain probability of early-onset disease. This report describes a patient who was screened positive for KD in New York State, had a likely pathogenic genotype, and showed markedly reduced enzyme activity but surprisingly low psychosine levels. The patient ultimately developed KD in late infancy, an outcome not clearly predicted by existing NBS algorithms. It remains critical that psychosine levels be evaluated alongside genotype, enzyme activity levels, and the patient’s evolving clinical presentation, ideally in consultation with experts in KD, in order to guide diagnosis and plans for monitoring. View Full-Text
Keywords: Krabbe disease; psychosine; newborn screening Krabbe disease; psychosine; newborn screening
Show Figures

Figure 1

MDPI and ACS Style

Corre, C.S.; Matern, D.; Pellegrino, J.E.; Saavedra-Matiz, C.A.; Orsini, J.J.; Thompson-Stone, R. Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report. Int. J. Neonatal Screen. 2021, 7, 28.

AMA Style

Corre CS, Matern D, Pellegrino JE, Saavedra-Matiz CA, Orsini JJ, Thompson-Stone R. Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report. International Journal of Neonatal Screening. 2021; 7(2):28.

Chicago/Turabian Style

Corre, Camille S., Dietrich Matern, Joan E. Pellegrino, Carlos A. Saavedra-Matiz, Joseph J. Orsini, and Robert Thompson-Stone. 2021. "Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report" International Journal of Neonatal Screening 7, no. 2: 28.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop